Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Dr. Armstrong on Detection of Chromosomal Defects in mCRPC

March 21st 2020

Andrew J. Armstrong, MD, discusses the use of circulating tumor cell to detect chromosomal instability in men with metastatic castration-resistant prostate cancer.

Cell-Free DNA Shows Potential in Identifying Transformed Castration-Resistant Neuroendocrine Prostate Cancer

March 20th 2020

Himisha Beltran, MD, discusses research evaluating cell-free DNA to identify therapy resistance in prostate cancer.

Dr. Hamid on the Exploration of Predictive Biomarkers in mHSPC Subtypes

March 20th 2020

Anis Hamid, MBBS, discusses the hypothesis of predictive biomarkers for newly diagnosed metastatic hormone sensitive prostate cancer.

Rapid Sequencing May Alleviate Sequencing Challenges in mCRPC

March 20th 2020

William K. Oh, MD, discusses sequencing challenges in prostate cancer, biomarker development, and the impact of the PRINT trial.

Dr. Armstrong on the Utility of AR-V7 as a Biomarker in Prostate Cancer

March 20th 2020

Andrew J. Armstrong, MD, discusses the utility of AR-V7 as a biomarker in prostate cancer.

Dr. Gomella on the Evolution of AR Inhibitors in Prostate Cancer

March 19th 2020

Leonard G. Gomella, MD, professor, chair of the Department of Urology, and director of the Sidney Kimmel Cancer Center Network, of Thomas Jefferson University Hospital, discusses the evolution of androgen receptor (AR) inhibitors in prostate cancer.

GnRH Antagonists Lead to Lower Odds of Cardiac Complications in Prostate Cancer

March 19th 2020

Eugene B. Cone, MD, discusses the advantages of the study, the need for such research, and the potential to broaden these efforts to more novel agents such as abiraterone acetate, enzalutamide, and immune checkpoint inhibitors.

mCRPC: Advice for Treatment During COVID-19

March 18th 2020

Management of mCRPC During COVID-19

March 18th 2020

Counseling Patients With mCRPC

March 18th 2020

CARD Trial In Metastatic CRPC

March 18th 2020

Cabazitaxel for the Treatment of mCRPC

March 18th 2020

Using Taxanes Frontline in Metastatic Prostate Cancer

March 18th 2020

Checkpoint Inhibitor Therapy in Prostate Cancer

March 18th 2020

PARP Inhibitors in Castrate-Resistant Prostate Cancer

March 18th 2020

Impact of the CARD Trial for Treating Metastatic CRPC

March 18th 2020

Repeat Molecular Testing in Advanced Prostate Cancer

March 18th 2020

Sequencing Therapy in Castrate-Resistant Prostate Cancer

March 18th 2020

The Use of Taxanes Earlier in Prostate Cancer

March 18th 2020

Dr. Agarwal on Impact of the TITAN Trial With Apalutamide Plus ADT in mCSPC

March 18th 2020

Neeraj Agarwal, MD, discusses the impact of the TITAN trial in metastatic castration-sensitive prostate cancer.